Fog/Mist 67°
Tag:

Merck

Business
Merck Stock Drops, Layoffs Begin In $3B Restructuring Plan Merck Stock Drops, Layoffs Begin In $3B Restructuring Plan
Merck Stock Drops, Layoffs Begin In $3B Restructuring Plan Merck, a pharmaceutical company headquartered in Rahway, announced it will be undergoing layoffs after a disappointing second quarter.  In its earnings report, Merck said it aims to save more than $3 billion in cost savings as part of a "multiyear optimization initiative."  The restructuring program includes eliminating certain administrative, sales and research and development positions. Merck did not say how many people would be laid off, but said they aim to achieve the cost savings by 2027.  To save money, the company plans to reduce office space and optimize its manufac…

SHARE

by Sam Barron
Business
COVID-19: Stop & Shop Pharmacies Now Offering Anti-Viral Medication COVID-19: Stop & Shop Pharmacies Now Offering Anti-Viral Medication
Covid-19: Stop & Shop Pharmacies Now Offering Anti-Viral Medication Stop & Shop has begun offering two approved COVID-19 antiviral medicines, Pfizer's Paxlovid and Merck's Molnupiravir at its 55 New York pharmacies. The mega-supermarket chain made the announcement on Thursday, April 7, that the drugs would be available at no cost with a valid prescription from a health care provider. The COVID-19 anti-viral medication Molnupiravir can be prescribed to those 18 and older, while Paxlovid is authorized for use by adults and children ages 12 and older weighing at least 88 pounds, store officials said. Availability of the anti-viral oral prescript…

SHARE

by Kathy Reakes
News
COVID-19: FDA Authorizes Second Antiviral Pill COVID-19: FDA Authorizes Second Antiviral Pill
Covid-19: FDA Authorizes Second Antiviral Pill For the second time in as many days, the Food and Drug Administration (FDA) has authorized the use of an antiviral pill to treat mild and moderate COVID-19 cases. On Thursday, Dec. 23, the FDA approved the use of Merck’s molnupiravir pill for emergency use authorization, a day after officials authorized the use of Pfizer’s COVID-19 treatment pill. Earlier story - COVID-19: FDA OKs First Authorized Home Treatment For Virus Merck’s pill has been cleared for use by adults 18 and older who have tested positive for COVID-19 and are at the greatest risk of being hospitalized or dying from t…

SHARE

by Zak Failla
News
COVID-19: FDA OKs First Authorized Home Treatment For Virus COVID-19: FDA OKs First Authorized Home Treatment For Virus
Covid-19: FDA OKs First Authorized Home Treatment For Virus The fight against COVID-19 took a step forward as federal health officials authorized the first pill that Americans will be able to take at home to head off the worst effects of the virus. On Wednesday, Dec. 22, the US Food and Drug Administration (FDA) granted emergency authorization for Pfizer’s COVID-19 treatment pill, which has been recommended for people at high risk of developing severe cases of COVID-19. The pill could be available as soon as this weekend, according to Pfizer CEO Albert Bourla. Related story - COVID-19: Pfizer Releases Data On Anti-Viral Pill's Effective…

SHARE

by Zak Failla
News
COVID-19: Drugmaker To Seek Emergency Approval For Pill To Treat Virus COVID-19: Drugmaker To Seek Emergency Approval For Pill To Treat Virus
Covid-19: Drugmaker To Seek Emergency Approval For Pill To Treat Virus A new pharmaceutical company is throwing its hat in the ring as the country continues its fight against COVID-19. Merck and Ridgeback Biotherapeutics announced on Friday, Oct. 1 that it is planning to apply for federal emergency approval of a pill that can reportedly help prevent hospitalizations and deaths in COVID-19 patients. According to the company, trials have found that the pill - dubbed molnupiravir - could potentially reduce the risk of hospitalization or death in patients with mild to moderate COVID-19 by approximately 50 percent. The results of the late-stage trial have bee…

SHARE

by Zak Failla
Lifestyle
COVID-19: Little Brown Pill Could Be Difference Maker In Fight Against Virus COVID-19: Little Brown Pill Could Be Difference Maker In Fight Against Virus
Covid-19: Little Brown Pill Could Be Difference Maker In Fight Against Virus Scientists may have cracked the code to help in the fight against COVID-19 and potential future pandemics. Though still in clinical trials, the “little brown pill” molnupiravir may give doctors and researchers a new tool and treatment as the country continues combating the latest wave of COVID-19 cases. Merck (also known as MSD), and Ridgeback Biotherapeutics, LP announced earlier this month that they ran a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy of the pill to eliminate the strain that causes COVID-19. According to the prelimin…

SHARE

by Zak Failla